Kelly A. Romano Buys 15,000 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) Stock

Athira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano acquired 15,000 shares of the stock in a transaction that occurred on Friday, June 21st. The stock was purchased at an average price of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the transaction, the director now owns 53,315 shares in the company, valued at $120,491.90. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Athira Pharma Stock Performance

NASDAQ:ATHA opened at $2.41 on Thursday. The stock has a fifty day moving average price of $2.35 and a two-hundred day moving average price of $2.71. The stock has a market capitalization of $92.38 million, a price-to-earnings ratio of -0.79 and a beta of 2.91. Athira Pharma, Inc. has a 1 year low of $1.33 and a 1 year high of $4.30.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.11. On average, analysts predict that Athira Pharma, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

Separately, JMP Securities reissued a “market outperform” rating and set a $19.00 price target on shares of Athira Pharma in a report on Thursday, June 20th.

Institutional Investors Weigh In On Athira Pharma

Several institutional investors and hedge funds have recently made changes to their positions in ATHA. Forefront Analytics LLC increased its holdings in Athira Pharma by 43.0% during the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after acquiring an additional 8,955 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of Athira Pharma in the fourth quarter valued at approximately $32,000. Clarius Group LLC increased its stake in shares of Athira Pharma by 35.8% during the 4th quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock worth $130,000 after purchasing an additional 14,124 shares in the last quarter. Mirador Capital Partners LP acquired a new position in shares of Athira Pharma during the 1st quarter worth approximately $57,000. Finally, Laird Norton Trust Company LLC lifted its stake in Athira Pharma by 21.3% in the 3rd quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after buying an additional 31,400 shares in the last quarter. 57.12% of the stock is currently owned by hedge funds and other institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.